Emanuel Krebs1, Thomas Kerr2, Julio Montaner2, Evan Wood2, Bohdan Nosyk3. 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada. Electronic address: bnosyk@cfenet.ubc.ca.
Abstract
BACKGROUND: Research into the avoided crime-related costs associated with methadone maintenance treatment (MMT) is sparse. Our objective was to characterize the dynamics in crime-related costs associated with MMT effectiveness among opioid dependent individuals in Vancouver, Canada. METHODS: We considered individuals enrolled in a prospective study between December, 2011 and May, 2013. Monthly crime-related costs (2013 CAD) were derived from self-reported criminal activity. On the basis of MMT receipt and illicit opioid use, individuals were classified in mutually exclusive health states: (i) MMT high effectiveness; (ii) MMT low effectiveness; (iii) opioid abstinence; or (iv) relapse. We classified individuals as daily, non-daily or non-stimulant users and controlled for demographic and socio-economic characteristics. A two-part multiple regression model was constructed; the first part modeled non-zero cost probability, the second estimated the level of costs. Avoided costs were estimated for each health state and stratified by stimulant use intensity. RESULTS: Our study included 982 individuals (median age 47, 38% female) for 2232 observations. Individuals on MMT with high effectiveness incurred lower monthly costs of criminality (avoided costs of $6298; 95% C.I. ($1578, $11,017)), as did opioid abstinent individuals ($6563 ($1564, $11,561)). Avoided costs for daily stimulant users were greater than for non-daily users, both for individuals on MMT with high effectiveness ($12,975 vs. $4125) and opioid abstinent ($12,640 vs. $4814). CONCLUSION: Using longitudinal data on individuals with a history of MMT, we found substantially lower costs of criminality associated with high effect to MMT. Avoided costs were highest among daily stimulant users that were on MMT with high effectiveness or those opioid abstinent.
BACKGROUND: Research into the avoided crime-related costs associated with methadone maintenance treatment (MMT) is sparse. Our objective was to characterize the dynamics in crime-related costs associated with MMT effectiveness among opioid dependent individuals in Vancouver, Canada. METHODS: We considered individuals enrolled in a prospective study between December, 2011 and May, 2013. Monthly crime-related costs (2013 CAD) were derived from self-reported criminal activity. On the basis of MMT receipt and illicit opioid use, individuals were classified in mutually exclusive health states: (i) MMT high effectiveness; (ii) MMT low effectiveness; (iii) opioid abstinence; or (iv) relapse. We classified individuals as daily, non-daily or non-stimulant users and controlled for demographic and socio-economic characteristics. A two-part multiple regression model was constructed; the first part modeled non-zero cost probability, the second estimated the level of costs. Avoided costs were estimated for each health state and stratified by stimulant use intensity. RESULTS: Our study included 982 individuals (median age 47, 38% female) for 2232 observations. Individuals on MMT with high effectiveness incurred lower monthly costs of criminality (avoided costs of $6298; 95% C.I. ($1578, $11,017)), as did opioid abstinent individuals ($6563 ($1564, $11,561)). Avoided costs for daily stimulant users were greater than for non-daily users, both for individuals on MMT with high effectiveness ($12,975 vs. $4125) and opioid abstinent ($12,640 vs. $4814). CONCLUSION: Using longitudinal data on individuals with a history of MMT, we found substantially lower costs of criminality associated with high effect to MMT. Avoided costs were highest among daily stimulant users that were on MMT with high effectiveness or those opioid abstinent.
Authors: Robert P Schwartz; Jerome H Jaffe; David A Highfield; Jason M Callaman; Kevin E O'Grady Journal: Drug Alcohol Depend Date: 2006-06-21 Impact factor: 4.492
Authors: Xavier Castells; Thomas R Kosten; Dolors Capellà; Xavier Vidal; Joan Colom; Miguel Casas Journal: Am J Drug Alcohol Abuse Date: 2009 Impact factor: 3.829
Authors: Fabian Termorshuizen; Anneke Krol; Maria Prins; Ronald Geskus; Wim van den Brink; Erik J C van Ameijden Journal: Drug Alcohol Depend Date: 2005-02-24 Impact factor: 4.492
Authors: Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis Journal: CMAJ Date: 2012-03-12 Impact factor: 8.262
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Robert P Schwartz; Pierre K Alexandre; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Jerome H Jaffe Journal: J Subst Abuse Treat Date: 2013-10-14
Authors: Sarah Larney; Nicola Jones; David A Fiellin; Suzanne Nielsen; Matthew Hickman; Timothy Dobbins; Thomas Murphy; Robert Ali; Louisa Degenhardt Journal: Int J Epidemiol Date: 2021-01-23 Impact factor: 7.196
Authors: Vivian T Reckers-Droog; Maartje Goorden; Marcel G W Dijkgraaf; Hester V Van Eeren; Kathryn E McCollister; Leona Hakkaart-van Roijen Journal: J Ment Health Policy Econ Date: 2019-06-01
Authors: Emanuel Krebs; Jeong E Min; Elizabeth Evans; Libo Li; Lei Liu; David Huang; Darren Urada; Thomas Kerr; Yih-Ing Hser; Bohdan Nosyk Journal: Med Decis Making Date: 2016-12-27 Impact factor: 2.583
Authors: Natasa Gisev; Chrianna Bharat; Sarah Larney; Timothy Dobbins; Don Weatherburn; Matthew Hickman; Michael Farrell; Louisa Degenhardt Journal: Lancet Public Health Date: 2019-06-11
Authors: Sarah Larney; Matthew Hickman; David A Fiellin; Timothy Dobbins; Suzanne Nielsen; Nicola R Jones; Richard P Mattick; Robert Ali; Louisa Degenhardt Journal: BMJ Open Date: 2018-08-05 Impact factor: 2.692